Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan paediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs.
Odevixibat is a potent and selective inhibitor of the ileal bile acid transporter (IBAT), sometimes also referred to as the apical sodium dependent bile acid transporter (ASBT), that has minimal systemic exposure at therapeutic doses and acts locally in the gut.
Albireo are developing odevixibat initially to treat patients with PFIC, a rare genetic liver disease, and plan to consider additional development in other paediatric cholestatic liver diseases and disorders in the future. Their Phase 3 program in PFIC includes a single randomized, double-blind, placebo-controlled, multicentre clinical trial and an open-label long-term extension study. The double-blind trial, called PEDFIC1, is underway with data read out anticipated in the Middle of 2020. (June/July).
The U.S. Food and Drug Administration (FDA) has granted to the odevixibat PFIC program or elements of it fast track, rare paediatric disease and orphan drug designations. The European Medicines Agency (EMA) has granted odevixibat orphan designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. Its Paediatric Committee has agreed to Albireo's odevixibat Pediatric Investigation Plan for PFIC. Both FDA and EMA also have granted orphan drug designation to odevixibat for the treatment of Alagille syndrome and primary biliary cholangitis. Albireo will commercialise Odevixibat in the US, Europe & Canada and will partner in remaining regions.
Job Title: Medical Science Liaison/Senior Medical Science Liaison
Reports To: VP and Head of Global Medical Affairs
The Medical Science Liaison is a field-based scientific and clinical expert who strategically supports Albireo’s medical and scientific objectives. The MSL is responsible for identifying, developing and managing peer-to-peer relationships with a variety of healthcare professionals including pediatric hepatologists, gastroenterologists and surgeons.
He/she will be accountable to engage in high quality communications regarding the science and clinical applications of portfolio to variety of external stakeholders, as well as obtain important insights about current practice, treatment landscapes, and emerging clinical and scientific data. In addition, the MSL is expected to build strong cross-functional relationships, as well as provide meaningful subject-matter experts, to other colleagues at Albireo, in a fully compliant manner.
Key Duties and Responsibilities:
Partnership & Commitment
We believe that people and relationships ultimately determine success. We are committed to achieving excellence in everything we do. We strive to identify, attract and develop the best talent for our business, focusing on execution and teamwork.
Enjoyment & Creativity
We encourage individual creativity but believe that team effort produces the best results. We promote opportunities to contribute, providing a positive environment of curiosity and development. In the rapidly changing world of drug development, we work to anticipate changes and develop innovative approaches to meeting our goals.
Mutual Trust & Respect
We value diversity and strive to provide an inviting and inclusive environment. We seek to inspire trust and respect by taking responsibility for our actions, maintaining high ethical standards and encouraging collaboration and honest and straightforward communication.
Equal Opportunity Employer
All applicants should be legally entitled to work for any employer in the U.S.
Note to employment agencies: Please do not forward any agency resumes.